Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Burn rate should be reduced by the conclusion of the Rett and AD trials, until additional trials are started.
Thank you powerwalker...thank you...WGT...
I like that Steve Forbes identifies himself as "Forbes Staff."
I think he and/or his foundation has bought a good number of shares in AVXL, SAVA and ANVS after his team did the research for this article.
I agree. The ATM is used on an as needed basis. If the revenues start coming in then the ATM won't be used. Sounds like a great way to line up funds.
Last time there was a big pop in the share price Missling used the ATM to raise a chunk of cash at the opportune time. To raise that same amount of money now or after that raise would take a lot more shares than it did at the time.
Seems like very good financial management to me.
So Powerwalker, then looks like that old expression ..."You are NOT CRAZY, they REALLY ARE AFTER YOU...!!!....comes to mind.
Steve Forbes Forbes Staff
“With all thy getting, get understanding."
Feb 7, 2023,06:00am EST
Why is there no cure for Alzheimer’s—or why aren’t there medications that can at least substantially slow or meaningfully ameliorate the disease? It afflicts more than 6 million Americans, with that number on its way to doubling within a generation.
Alzheimer’s is a hideous ailment for both the sufferers and their families and friends. Yet even though the disease was first diagnosed by psychiatrist Alois Alzheimer in the early 1900s, progress in fighting it has been almost nonexistent. What’s scandalous is that for decades research has been almost entirely focused on the wrong hypothesis.
Dr. Alzheimer noted in the autopsy of the patient’s brain with the disease that came to bear his name that it was densely loaded with two proteins called plaques and tangles. Unfortunately, the dominant thesis in research on the disease has been that attacking plaques, and to a lesser extent tangles, would cure the ailment and enable the brain to regain its health.
Alzheimer himself warned about focusing too much on plaques and tangles as causes. In fact, some sufferers of Alzheimer’s have proved to have had little in the way of plaques, while others who had plaques didn’t have the disease.
Nonetheless, despite constant failures—some 20 drugs have been developed that ended up as flops—and the expenditure of tens of billions of dollars, the main thrust of research remains focused on fighting plaques.
The obsession with this dead-end approach has been fanatical, almost cultlike. Researchers who want to pursue more promising avenues have faced serious obstacles. Rarely has chronic failure resisted correction on something so important.
You may have heard of a new drug called lecanemab, which is being heralded as a fantastic breakthrough. But lecanemab is based on the wrongheaded plaques hypothesis. As noted health policy journalist Joanne Silberner sadly points out, “At best, lecanemab might slightly slow a patient’s inevitable decline for a few months.”
This research scandal shows the danger of groupthink, particularly when there’s a powerful government agency such as the National Institutes of Health putting the kibosh on grants for nonconsensus projects.
A classic case of similar groupthink involved the cause of stomach ulcers. The once-prevailing view was that stress and lifestyle were the cause, and drugs and regimens were developed on that belief.
This dogma was challenged by two Australian physicians, Robin Warren and Barry Marshall. They posited that the villain was bacteria and that antibiotics were the answer for a permanent cure. When not ignored, their discoveries were derided. Only after many years and constant, sometimes unorthodox advocacy, especially by Dr. Marshall, did the medical world accept their truths. The two were eventually awarded the Nobel Prize in Medicine.
In the case of Alzheimer’s, the rigid research mentality has begun to soften, but only slightly. To attack this deadly rigidity, Congress should hold hearings on the subject, starting with the leaders at the National Institutes of Health.
Steve Forbes is Chairman and Editor-in-Chief of Forbes Media.
https://www.forbes.com/sites/steveforbes/2023/02/07/the-scandal-of-alzheimers/?sh=34284da66a41&bsft_aaid=a4679c91-eb03-4591-93c2-79b7f25f9cbd&bsft_eid=15374f1b-1165-4402-b482-cdabfc723dde&utm_source=blueshift&bsft_clkid=39bb3ca5-f842-4f84-a918-78a3d2514c58&bsft_uid=8a4ab049-cac4-4359-ae99-bc1e70d3b870&bsft_mid=6fae9050-ef21-411e-9d1c-4e5f7b0849ca&bsft_utid=8a4ab049-cac4-4359-ae99-bc1e70d3b870-DRPROOF&bsft_mime_type=html&bsft_ek=2023-02-07T21%3A30%3A36Z&bsft_lx=20&bsft_tv=4&pk=ce01a6586b8394cd219d9d4151b05359&utm_campaign=DAP_ISSUE_02.07.23&utm_medium=email&vid2=9cd562d8abdeeda86039a61cc7e5dc63e585d49a727e626584f7ccd81870dffd80f6507937c7784a56ba72af38c88171
Bullish
BULLISH
Not SO worried about catastrophic monetary collapse, just an extended
period of "real cost" borrowing.
It has been an amazing decade or so of absolutely FREE money for many.
Some of those (Corporate and Retail alike) will be ill prepared to
roll accumulated debt to current instruments.
nidan, I like that Steve Forbes identifies himself as "Forbes Staff."
I think he and/or his foundation has bought a good number of shares in AVXL, SAVA and ANVS after his team did the research for this article.
Puzzle me this....
IF the current burn rate WILL rise in part at least by added staff
let alone trial(s) expense
How long does $140M last while considering lead time to raise?
There was never any prospect of a pharma partnership this year or any other year, nor any prospect that the so-called phase 2B/3 AD trial would be pivotal. It’s amazing to watch this 3rd rate company and CEO year in and year out pulling the same well-worn nonsense, and it’s even more amazing that there are still people who continue believe it hook, line and sinker. It’s no wonder the shorts are all over this thing.
FUD = Facts, Understanding and Data, except in Candyland where a few people still believe in fairy tales.
Anavex is a good trading stock but that’s it.
All the more reason to raise money now, if one suspects an economic collapse and the cost of borrowing to increase a few years from now.
Nobody was pleased with the decision to sell stock in 2021, but that turned out to be a prudent short-term move to shore up the balance sheet. It's much harder to acquire a financially healthy company for cheap than one that has the potential to become a money pit for the acquirer.
It isn't about the money...it is about the lie..."no new taxes"...
Diversity, most importantly.
As Moon pointed out, I bonds best deal on the street....but restricted.
The only long term rate I advantage is existing mortgage(s).
Old enough to remember 11% 30year and a generation is complaining
about 6-7%.
Missling included, lets see how cost of money affects the next few years.
It's an insurance policy. Nothing more. It'll cost a small amount of capital to secure the right to raise money in the future, if it's needed.
I don't see what the big deal is. But for the sake of argument let's suppose that Dr. Missling taps into his 200mm authorized share limit and forces LPC to purchase the full $150mm worth of shares, at say $10/share. Anavex would then have $290mm in cash, no debt, and just over 100mm shares outstanding.
What's so bad about that situation? This is a non-issue. LPC funding was much scarier when the stock traded under $2.
They have 4 years cash with their currently plans
Even at 6.89%, Series I Bonds still look a heck of a lot better than anything else out there. Only negative is the lousy $10K annual limit :(
Not bad. I bonds also look attractive, just not as much as last May when the rate was over 9%
Yeah, I'm content with my 17 week T-Bills that will bring me 4.78%. Of course, I bought another Series I Bond (biggest no-brainer out there - too bad only limited to $10K per year) that will bring me 6.89% through April.
IMO you can't have a "portfolio" without at least some of these types of investments...
I just got 5% on 11 month FDIC CD @5%.
May not appeal to WGT, but as part of a portfolio?
Steve Forbes Forbes Staff
“With all thy getting, get understanding."
Since they have 140mm in the bank now I suspect he wouldn't until share price exceeds 50 dollars.
Chances are that, when the share price exceeds 50 dollars, they will have enough revenue/profit coming in that would preempt the need for raising capital.
I believe the raise is twofold...
1). We are going RETT alone (most likely approval early 2024), so there will be funds needed to get the ball rolling. In fact, the ball has started to roll (i.e. recent new hires). TGD likes to maintain a hefty cash balance. As expenses increase, so will his appetite to increase the hoard. Remember we are going it alone on rare diseases so once RETT is approved, others will shorty follow, which will require money.
2). I'm slowly leaning toward a P4 (vs. outright approval) for AD and thus the case to raise cash. Most likely will be announced after RETT data in July. Remember a P4 will cost big dollars to monitor everyone prescribed!!!!
There will be another run (as high as 30+) very very soon, so IMO, TGD will raise then. Also keep in mind most here, when calculating share price, anticipate shares increasing. This recent LPC is just one of them.
Now that RETT is over, expect anecdotal news to start appearing more frequently.
All is good!!! We shall see 13 by end of week...Just watch!
Who's to say they will be needing capital any time soon, a shelf placement is more of a contingency. Missling has control of when and if shares will be sold. Since they have 140mm in the bank now I suspect he wouldn't until share price exceeds 50 dollars.
They also said they didn't need dilution...so how does the comment about not yet meeting with the FDA have any truth to it.
They also have seen the data which triggered the silent money grab...guess they don't want to PR about the money...lol
Yep seems like a good move to me.
First off they need feedback from the FDA on whether another P3 is even needed and that meeting hasn't yet happened according to the last call. Missling just yesterday again released that their trial met both its co-primary and key secondary endpoints, showing statistically significant and clinically meaningful improvement in cognition and function as measured by ADAS-Cog, ADCS-ADL, and CDR-SB, respectively.
We're not the only small bio doing this - Annovis Bio Announces Approval For European Union Clinical Trial Sites For Phase 3 Study Of Buntanetap For Treatment Of Parkinson's Disease
Good post on Stocktwits by Trainguy1--and I agree fully !! It’s well known that the people who least need to borrow money are the people offered the best interest rates. Similarly in businesses, a company that demonstrates its readiness to operate independently gets the best partnering offers. Even though we know Anavex wants to partner, they need to demonstrate complete readiness to operate independently. It’s a serious game of chicken. By signing the Lincoln Park agreement, Anavex is saying they’re ready to play. Game on!
There are 2 ways to read your question:
1. Will AVXL be selling Blarcamesine within 6 months, as in will the drug be available on the open market?
2. Will AVXL be selling Blarcamesine within 6 months, as in will the company license or sell the rights?
I think you were referencing #2, but the answer to both is most likely "no." I expect at this point Dr. Missling is confident enough to submit to the FDA without a partner, and if approved maximize the leverage he has entering negotiation. At worst, he'll be told to run another confirmatory P3 trial -- and he has the cash to do so with minimal dilution. More likely, he'll be asked to run a P4 trial -- and with the LPC deal he'll have the cash to continue advancing the rest of the pipeline.
Sold plenty awhile ago...it has to fill that gap in the 8's sometime.
LOL...listen to the call...it is about BS...he has been feeding you lines for years...what does no more dilution mean to you?
Missling recently said...there is absolutely no reason for further dilution...in Missling we trust...yeah...we trust that there will be more lies. He must now be finished going through the data...his lack of enthusiasm, lack of timeline commitment to data, and lack of keeping to his word about dilution means one thing...data isn't good enough for a partner with up front payments. Need lots if money for a large P3.
They have 4 years cash with their currently plans...came from the horses mouth.
Sure do have a basis. A partner brings a fat upfront payment...but they have to scrape together a lousy 150 million...the amount of the voucher...must not be expecting good rett news if they cannot get the pediatric voucher withing the 4 years for which they already have enough funding.
Maybe you should stop being so laughable and but 2 and 2 together. A nice rett voucher or a partner would not require a bunch of money if you are planning on your current funds to get you through 4 years
I even spelled it out for you 2 different ways.
What’s 6 months? They have enough cash for 3 years
Again listen to the conference call.
It is not about the start, it is about a good start, in order to finish strong.
Missling the forest for the trees is very common around here.
We have data from the two largest indications (markets $$$$$) to be broken down and explained (AD P2/P3, PDD OE).
But you want trial announcements? really?
Beats the schhhiiiiet out of me.
He has been promising to start many of these new trials for some years - so he repeats it this year - we have to see which actually he starts
I mean is better than playing with toilets.
But not quite as good as a real brain when it comes to bullshit detection.
I guess you dont own any insurance on anything you do?
Hey investor, did you sell any trading shares or core yesterday after the conference call?
Asking for a friend.
Or perhaps the analysts you speak about were cleaning toilets as well.
Imagine being a share holder and not being able to listen to the call because of toilet cleaning duties.
Perhaps the analysts are losing interest and had better things to do this morning.
I’ve been cleaning my toilet.
Powerwalker:
Thank you very much for that post.......what a great article and Steve Forbes is a clear thinker who gets it!
EBZ. I think that is premature emasculation.
LOL...no dilution...hahahaha...they can't get a partner and now have to go at it alone.
To maintain that $140 Million on hand. Does anybody think they will be selling 2-73 within 6 months?
I just got 5% on 11 month FDIC CD @5%.
Very interesting that during the CC that foreign countries drug regulators could be focusing on Anavex and possible approval of Anavex drugs and, Anavec very aware of this ... and the possibility that our FDA would need to play catch-up
They obviously cannot get a partner for an unproven new science...
they can't get a partner and now have to go at it alone.
They obviously cannot get a partner for an unproven new science...
Followers
|
1067
|
Posters
|
|
Posts (Today)
|
16
|
Posts (Total)
|
461374
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |